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During pregnancy, a series of physiological changes are determined at the molecular, cellular 
and macroscopic level that make the mother and fetus more susceptible to certain viral and 
bacterial infections, especially the infections in this and the companion review. Particular 
situations increase susceptibility to infection in neonates. The enhanced susceptibility to certain 
infections increases the risk of developing particular diseases that can progress to become 
morbidly severe. For example, during the current pandemic caused by the SARS-CoV-2 virus, 
epidemiological studies have established that pregnant women with COVID-19 disease are more 
likely to be hospitalized. However, the risk for intensive care unit admission and mechanical 
ventilation is not increased compared with nonpregnant women. Although much remains 
unknown with this particular infection, the elevated risk of progression during pregnancy 
towards more severe manifestations of COVID-19 disease is not associated with an increased 
risk of death. In addition, the epidemiological data available in neonates suggest that their risk of 
acquiring COVID-19 is low compared with infants (<12 months of age). However, they might be 
at higher risk for progression to severe COVID-19 disease compared with older children. The 
data on clinical presentation and disease severity among neonates are limited and based on case 
reports and small case series. It is well documented the importance of the Zika virus infection as 
the main cause of several congenital anomalies and birth defects such as microcephaly, and also 
adverse pregnancy outcomes. Mycoplasma infections also increase adverse pregnancy outcomes. 
This review will focus on the molecular, pathophysiological and biophysical characteristics of 
the mother/placental-fetal/neonatal interactions and the possible mechanisms of these pathogens 






































































ACE2  Angiotensin-converting enzyme 2 receptors            
AF                        Amniotic Fluid 
Ang 1-7                Angiotensin 1-7  
APTT                   Activated partial thromboplastin time 
ARDS  Acute respiratory distress syndrome 
AT1R                   Angiotensine type 1 receptor 
B/L7                     Cathepsin B/L7  
BV                        Bacterial Vaginitis 
CDC                    Centers for Disease Control and Prevention, USA 
CMV                    Cytomegalovirus  
COVID-19  Coronavirus disease 2019 
CoVs  Coronaviruses 
CS                        Cytokine Storm 
CSF                      Cerebrospinal Fluid 
DIC                      Disseminated Intravascular Coagulation  
FRC                     Functional residual capacity  
GFR                     Glomerular filtration rate 
HIV                      Human Immunodeficiency Virus 
HSV                     Herpes Simplex Virus 
ILs  Interleukins 
MAS                    Macrophage Activation Syndrome 
MasR                   Mas Receptor (for Angiotensin 1-7) 
MIPL                   Medically Induced Premature Labor 
NK                       Natural Killer 
NGS                    Next-Generation Sequencing 
NF-B   Nuclear factor kappa-light-chain-enhancer of activated B cells 












RAS                 Renin–angiotensin–aldosterone system  
S          Spike Protein 
SPL                  Spontaneous Premature Labor 
SVR                 Systemic vascular resistance 
TMPRSS2        Type II transmembrane serine protease 
TORCH               Toxoplasmosis, Rubella, Cytomegalovirus and Herpes Virus-like 
infections 
TNF-α          Tumor necrosis factor-  
WHO         World Health Organization  





































1 Physiological changes during pregnancy  
To better understand the pathophysiological and molecular considerations 
of viral and bacterial infections during pregnancy, a general background of the 
physiological changes during pregnancy is needed. In general, the increased 
physiological requirements during pregnancy due to the stress of carrying growing 
offspring in their bodies until delivery may explain the higher incidence of preterm 
delivery and stillbirths when additional stress is created by certain infectious 
diseases. This is also compounded by additional pre-existing clinical conditions, 
such as obesity, metabolic and cardiovascular diseases, and other conditions that 
can affect pregnant women during and after labor [1,2]. Pregnancy is associated 
with early vasodilation of the systemic vasculature, and especially the maternal 
kidneys, and systemic changes in particular, such as changes in hormone levels [3]. 
These necessities changes allow a pregnant body to adapt to meet the increased 
circulatory and metabolic demands of the mother and fetus and to ensure adequate 
uteroplacental circulation for fetal growth and development. These and other 
factors are relevant to understanding the effects of emerging infectious diseases in 
pregnancy. 
The systemic vasodilation associated with pregnancy occurs as early as 5 
weeks after conception and then proceeds until full placentation and the complete 
development of the uteroplacental circulation [4]. This vasodilation is mediated by 
endothelium-dependent factors, including nitric oxide synthesis that is upregulated 
by estradiol, progesterone, and possibly vasodilatory prostaglandins (PGI2) and 












during pregnancy [7,8]. Relaxin is a peptide produced by the corpus luteum 
during pregnancy, detectable in the luteal phase of the ovulatory cycle [9]. All 
these changes result in a 25–30% fall in systemic vascular resistance (SVR). To 
compensate for this the cardiac output increases by approximately 40% during 
pregnancy [8,10]. The fall in SVR likely triggers the renin-angiotensin–aldosterone 
system (RAS) to retain sodium and increase plasma volume. Because of the 
changes in SVR, adaptive responses by the heart also occur during pregnancy to 
maintain adequate pressure and flow rates. This is achieved mostly by an increase 
in the heart stroke volume and secondarily by an increase in heart rate. The 
maximum cardiac output is found at about 20–28 weeks gestation [3]. This higher 
demand in cardiac function necessitates healthy hearts in pregnant women. Also, 
during labor, there is a further increase in cardiac output (15% in the first stage and 
50% in the second stage). The sympathetic response to pain and anxiety further 
elevates the heart rate and blood pressure. This is relevant in some adverse 
outcomes of blood pressure during pregnancy (i.e. preeclampsia, gestational and 
chronic hypertension, and a mixture of these). Importantly, infectious diseases can 
affect the cardiovascular system and its functional reserve, which changes during 
pregnancy, and can have an important impact on pregnant women.   
During pregnancy, there are functional changes in the maternal respiratory 
system. Oxygen demand increases significantly resulting in a 40–50% increase in 
minute ventilation, mostly due to an increase in tidal volume, rather than in the 
respiratory rate. This maternal hyperventilation causes arterial pO2 to increase and 












[11]. The diaphragmatic elevation by the gravid uterus and the gestational weight 
gain are responsible for altered pulmonary volumes leading to a reduced total lung 
capacity and to an inability to clear effectively pulmonary secretions [11–13]. The 
expiratory reserve volume and functional residual capacity (FRC) decrease, while 
vital capacity remains unchanged. This is compensated for by hyperventilation and 
a tidal volume increment by progesterone-dependent stimulation of the respiratory 
center [13,14].  
Since hyperventilation leads to more air uptake over time, pregnant 
women are more likely to acquire emerging infectious diseases carried by airborne 
droplets, aerosols, and other sources of infections [15]. In addition, there are 
progesterone-mediated changes in the nasal mucosa. As a result, microorganisms 
are difficult to eliminate because of the inability to clear pulmonary secretions 
efficiently and the adhesion properties of microorganisms, especially in the upper 
respiratory tract [11–13,15]. 
Maternal immunological changes during pregnancy are characterized by a 
strong first-line-of-defense response against viral and bacterial pathogens mediated 
by effective activations of Natural Killer (NK) cells and monocytes [15–17]. 
However, once the first host response barrier is overcome, the second line of 
defense is also partially defective due to the attenuation of cell-mediated immunity 
responses by helper lymphocytes type 1 (known as the Th1 response) [15–18].  In 
addition, the Th2 response mediated by helper lymphocytes type 2, which 
potentiate humoral responses by Th2 cells, is enhanced. The imbalance between 












burden and eventually increased morbidity from intracellular pathogens, like the 
emerging infectious diseases considered in this special edition [15,17–20]. As the 
Th1 host immune response declines, the chances of developing “cytokine storms” 
(CS) are also diminished or dysregulated in comparison with non-pregnant women 
[16,17,20,21]. In parallel with this, during pregnancy the microbicidal, pro-
inflammatory Th1 cytokines, such as interferon-ɣ and interleukins (IL), IL 1α, 1β, 
12 and 6), are reduced or diminished in their activities, and the anti-inflammatory 
Th2 cytokines, such as IL-4, IL-10, IL-13 and transforming growth factor-beta 
(TGF-ß), are increased in their activities [15–17]. There are relative variations in 
these responses during the different trimesters of gestation in pregnancy [16].  
During normal pregnancy, the levels of blood fibrinogen and D-dimers 
increase, whereas the activated partial thromboplastin time (APTT) and 
prothrombin time decrease due to increases in the majority of the coagulation 
factors in plasma. Because of this, pregnancy is a condition with a higher risk of 
thrombotic incidents  [22,23].  
Renal diseases are frequently found in pregnant women partially because 
of the hormonal and hemodynamic changes that occur during pregnancy that can 
impact renal function, leading to less functional reserve [24,25]. The kidneys 
increase in length and volume, and physiologic hydronephrosis occurs in up to 
80% of women during pregnancy [24,25]. Hormonal changes during 
pregnancy allow for increased blood flow to the kidneys and altered renal 
autoregulation, such that glomerular filtration rate (GFR) increases significantly 












a result, the GFR increases by approximately 50% with subsequent decreases in 
serum creatinine, urea, and uric acid values. The antidiuretic hormone secretion is 
generally depressed, resulting in lower osmolality and serum sodium levels, 
whereas the rise in progesterone levels protects the pregnant woman from 
hypokalemia [24,25].  
The various physiological changes seen during pregnancy are summarized 
in Fig. 1, left panel. In Fig. 1, right panel, we have summarized some of the 
important properties of the diseases relevant for this review. 
 
2. The placenta and the possibilities of vertical transmission in 
emerging diseases like Sars-CoV-2 virus, Zika virus, and 
Mycoplasma 
 
2.1. The human Fetal-Maternal Interface  
 
The placenta forms the primary barrier between the maternal and fetal 
compartments throughout pregnancy, mediating the exchange of gases, nutrients, 
and waste products between these compartments. This transitory organ is formed by 
the interaction between embryo trophoblastic cells and maternal uterine 
endometrium. In humans, the primitive trophoblast layer differentiates into various 
tissues: (a) syncytiotrophoblast, which is an invasive cell layer that allows the 
blastocyst to erode the endometrium to reach direct contact with the maternal blood 












syncytiotrophoblast, allowing their continuous expansion; and (c) invasive 
extravillous cytotrophoblast, formed by cytotrophoblast cells extending beyond the 
syncytiotrophoblast and making contact with the endometrium, instigating 
anchoring villi, and invading the endometrial stroma. The syncytiotrophoblast 
delineates intercommunicating lacunae filled with maternal blood. The 
trophoblastic masses between the lacunae are the basis for the further development 
of the villous trees of the placenta. The core of the placental villi will be gradually 
filled with extraembryonic mesoderm that will become vascularized with 
embryonic blood vessels [26].   
Syncytiotrophoblast is responsible for the exchange of nutrient molecules as 
well as placental hormone production, and they provide a defense barrier against 
pathogenic microorganisms. Its functionality can be diminished by diseases and 
adverse conditions, such as hypertension and pre-eclampsia [27,28]. Early in 
pregnancy, the cytotrophoblast forms into a continuous layer beneath the 
syncytiotrophoblast, and as pregnancy advances, the cytotrophoblastic layer 
becomes incomplete. The stromal core of the chorionic villi contains fetal blood 
vessels immediately surrounded by endothelial cells and then by an extracellular 
matrix containing Hofbauer and mesenchymal cells. Hofbauer cells are a 
specialized type of macrophage that has been described as anti-inflammatory type-
M2 cells that promote maternal tolerance towards the fetus. They have also been 
implicated in tissue remodeling and control placental angiogenesis and villous tree 
growth and branching. As immune cells, they have been implied in vertical 












controlling viral infections [29]. In the development of the early placenta, fetal 
vessels are located away from the trophoblast, but as pregnancy progresses they 
become located in close contact with the trophoblast. 
In the third trimester, fetal capillaries within the villi are separated from 
maternal blood by a very thin layer of syncytiotrophoblast, seen as a vascular-
syncytial membrane [30]. Between the syncytiotrophoblast and endothelial cells, 
the extracellular matrix is reduced to allow the fusion of both basal laminae, which 
act as filters [31]. All of these changes (relocation of blood vessels, thinning of 
syncytiotrophoblastic layer, and cytotrophoblast discontinuity) are indicators of 
placental maturation [26].   
Pre-decidual endometrial changes begin during the menstrual cycle, even 
without embryo implantation [32]. The endometrial stromal cells further react to 
trophoblast invasion by increasing decidualization. The decidual stroma is 
characterized by its edematous structure and strong infiltration of immune cells, 
such as uterine NK cells, macrophages, and T cells, which play an important role in 
the placentation process and the remodeling of the spiral arteries [32]. The 
structural human maternal-placental interphase is shown in Fig. 2.  
 
2.2. Placental transmission of viral and mycoplasmal infections  
 
Several mechanisms may be used by pathogens for maternal-fetal 
transmission, including hematogenous spread, trophoblastic transcellular or 
paracellular pathways, or transport within immune cells. Although the 












microorganisms. Some viruses and mycoplasmas may cross this barrier and other 
sectors of the placenta, such as decidua, extravillous trophoblast. In addition, fetal 
membranes might be also involved in pathogen transference. Also, infectivity can 
vary throughout gestation, and it is probably associated with changes related to 
placental maturation [33,34]. Two main routes are used to infect the placenta: the 
ascending intrauterine route, which is the predominant one in bacterial infections, 
and the hematogenous route. Microorganisms invading the maternal-fetal interface 
via the hematogenous route are less common than those implicated in bacterial 
ascending infections [33–35]. Microorganisms that invade the placenta by the 
hematogenous route include Listeria monocytogenes [36], Zika virus [37,38], 
Treponema pallidum [35], Cytomegalovirus [39], Plasmodium species [40], and 
microorganisms causing toxoplasmosis, syphilis, varicella-zoster, including 
parvovirus B19, Rubella, and Herpes infections (TORCH infections) [41]. These 
microorganisms gain access through the maternal circulation to the intervillous 
space, from there they invade the villi and eventually the fetal circulation. In contrast 
to the ascending infections that cause inflammation primarily in the choriodecidua 
and amnion, microorganisms invading via the hematogenous route cause 
inflammation primarily in the placental villi and intervillous space [42].  
Pathogenic microorganisms have developed distinct strategies to invade and 
colonize maternal and fetal tissues. This can vary throughout gestation or with the 
level of maternal infection or corresponding host immune responses. For example, 
cytomegalovirus replication takes place in cytotrophoblast cells where the virus 












which also transports IgG immunoglobulins throughout the syncytiotrophoblast 
during the second half of pregnancy [39]. The extravillous trophoblast is the main 
target for initial infections by Toxoplasma gondii, Listeria monocytogenes, and Zika 
virus. Most of these pathogens also infect maternal leucocytes in the decidua, which 
might facilitate transfer to extravillous trophoblasts [35]. Since Hofbauer cells are 
localized in villi, they have been implicated in the spread of some infections, such 
as Zika or HIV-1 [43].  Less information is available about mycoplasma vertical 
transmission, although congenital infections in newborns are associated with the 
presence of mycoplasma in placental tissues [44,45].  As of this date, precise data 
on the vertical transmission of the SARS-CoV-2 virus in pregnant women has not 
yet become available. In mothers with mild or moderate COVID-19 disease, the 
newborn's delivery is usually at term; however, in those patients with severe 
COVID-19 disease, it is common to find preterm births, either spontaneous births or 
because of medical indications [46,47,56,48–55]. Though they are not commonly 
observed, spontaneous abortions and fetal demise have been reported [49,54,57]. 
Despite this, there is no direct evidence of SARS-CoV-2 placental infection in 
pregnant women with COVID-19 disease, although there are several recent reports 
on abnormalities in the morphologies of the placenta in these women [58,59]. The 
abnormalities include perivillous fibrin, fetal and maternal vascular malperfusion, 
and infarctions in several places [60,61]. These pathologies in the placenta of 
pregnant women with COVID-19 disease have been found despite the rare detection 












this has been observed in women with mild to moderate COVID-19, usually with 
comorbidities like hypertension, eclampsia, or gestational diabetes [59].  
Viremia caused by the SARS-CoV-2 virus is generally low and found only 
in 1% of symptomatic COVID-19 cases [63], which may play a role in the low 
incidence of vertical transmission detected in pregnant women. This virus has been 
detected in the amniotic fluid, the umbilical cord blood, and in the placentas of 
infected women [51,64,65]. However, recent literature provides some evidence that 
vertical transmission of SARS-CoV-2 is possible, although this appears to occur 
only rarely [66,67]. In general, the passage of this coronavirus through the placenta 
increases with increasing gestational age. However, the severity of fetal injuries 
decreases, once embryo/fetal development proceeds towards the end of pregnancy. 
Some of the damage may be driven by abnormal immune responses [59]. Studies 
suggest that maternal COVID-19 disease in the late second or third trimester is 
associated with more severe disease morbidity, and this requires increased 
surveillance than is necessary for early pregnancy [68,69]. Recently, a mother 
infected in the last trimester with SARS-CoV-2 delivered an infected neonate. In 
this particular case, the placenta showed signs of acute and chronic intervillous 
inflammation and was positive for the SARS-CoV-2 virus. Both maternal and 
neonatal blood samples were also positive for this virus, indicating for the first time 
that transmission may have occurred through the placenta [70]. Also, direct 
evidence of SARS-VoV-2 viral invasion in the placental tissue exists, as virions 












However, there is a pressing need for more research in this area, as the data remain 
inconclusive.  
 
2.3 Understanding the molecular basis of virus placental infections  
 
A key factor in preventing the deleterious effects of COVID-19 disease during 
pregnancy is to understand the mechanisms of vertical transmission of the emergent 
SARS-CoV-2 virus. Specifically, if the machinery that permits the entrance and 
replication of the virus is present in the placenta and chorion amnion, we can 
speculate that the virus uses the same mechanisms of host invasion as in other 
tissues, despite viremia being low [63]. However, the syncytiotrophoblast can 
modulate the immune response to a viral infection, since it is a part of the maternal-
interface barriers [39,72]. Placental cells can initiate local and paracrine immune 
responses through membrane vesicles containing microRNAs that confer resistance 
to viral infections [72,73].  
Research on SARS COV-2 host epithelial cell entry has been focused on 
ACE2, known to be the receptor of SARS-CoV-2. The expression pattern of 
ACE2 across more than 150 different cell types corresponding to all major 
human tissues and organs has shown expression of ACE2 in the placenta [74]. 
However, cell entry and the spread of SARS-CoV-2 viruses are widely thought 
to depend on the ACE2 receptor [75] and also the serine protease TMPRSS2 
[76], with likely participation of B/L7 [77] and furin protease [78]. Using 












express ACE2 and TMPRSS2 in the placenta, concluding that this is not a likely 
pathway for vertical transmission of the SARS-CoV-2 virus [79]. ACE2 has 
been localized by immunocytochemistry in cytotrophoblasts, 
syncytiotrophoblast, endothelium, and vascular smooth muscle [80]. It is worth 
mentioning that ACE2 plays a central role in placentation, the migration of 
trophoblasts, vasodilation in the mother, and vascular remodeling [81]. Because 
of this, the presence of ACE2 receptors seems to be related to adverse outcomes 
during viral involvement in pregnancy, such as miscarriages, preeclampsia, and 
ectopic pregnancy occurring during viral infections [80]. In contrast with ACE2 
receptors, the expression of TMPRSS2 has not been consistently observed in 
pregnancy-associated complications [77,82]. The receptor for ZIKV in host cells 
has not yet been identified, although laboratory studies suggest that the receptors 
could be AXL or TIM1 receptors [83,84]. AXL is a cell 
surface receptor tyrosine kinase, part of the TAM family of kinases 
(abbreviation for Tyro-3, AXL, and Mer Tyrosine-kinase receptors) [84,85].  It 
is involved in the stimulation of cell proliferation, aggregation, and survival 
through the activation of several downstream pathways (PI3K-AKT-mTOR, 
MEKERK, NF-κB, and JAK/STAT) [85]. ALX is important in processes related 
to cell growth, differentiation, and proliferation, and it is also involved in 
oncogenesis and cell development. It is additionally an inhibitor of host immune 
responses [86], and it is expressed in many cells in which ZIKV shows positive 
tropism. The results on ZIKV receptors with human cells, however, have been 












receptors) are glycoproteins that can interact with phosphatidylserine, either 
derived from apoptotic cells (contributing to the dead cells’ clearance) or viral 
membranes [87]. These receptors have been found on most of the cells for 
which ZIKV has shown positive tropism [37]. Other proteases that could 
contribute to viral entry have not been thoroughly investigated. Epidemiological 
and experimental studies have made it clear that the ZIKV is attracted to 
different tissue and cell types, especially the special stem neural cell types 
(neurotropism). In these cells, ZIKV exhibits high levels of viral replication, 
apoptosis, and alterations of the cell cycle. This might explain the sequelae 
observed in newborns exposed to the virus while being in an intrauterine 
environment [88,89]. As mentioned above, ZIKV expresses neurotropism for 
neural stem cells, promoting direct damage and producing sequelae and 
deformations as a result of this damage [89]. In mimicking this type of 
neurotropism in vitro it has been found that the infection of neural cells by 
ZIKV replicating at high efficiency in tissue cultures of human cell lines induces 
apoptosis and damage of neural tissue through the activation of caspase-3 
[90,91].   
The relationship of ZIKV with microcephaly is statistically significant 
for the entire affected population infected with ZIKV. In addition, because of 
the detection of the ZIKV RNA in amniotic fluid, placenta, and fetal brains, this 
virus has also been closely associated with microcephaly [92–94]. ZIKV 
invades the villi without infecting the syncytiotrophoblast and thus the virus 












ZIKV [95], resulting in a key role of the infection of the maternal residual 
tissues to explain the pathogenesis of ZIKV infection in the maternal-fetal 
interface, with its consequences in the embryo and fetus [96]. ZIKV replicates in 
proliferating explants from first-trimester human placentas, being these cells 
possible locations for the propagation of the infection [97]. During this stage, it 
has been established that ZIKV has a wide cell and tissue tropism in the 
maternal-fetal interface [98].   Positive tissue tropism and replication of the 
virus in placental cells during pregnancy has been demonstrated in vivo and in 
vitro [37]. ZIKV does not only infect placental cells, but it can also infect 
placental macrophages [99]. This can lead to congenital anomalies alongside 
placental insufficiency and delayed fetal growth. Fetal death is also associated 
with ZIKV infection during pregnancy [100,101]. 
During maternal infection by ZIKV, the ZIKV released into blood can 
easily reach the placenta and be transmitted to the fetus [102]. However, the 
degree of fetal infection by the virus is determined by the time when the 
infection took place during pregnancy. If acquired during the first trimester of 
pregnancy, the more frequent appearance of the encephalic sequels and the 
greater degree of microcephaly is usually observed [103]. It is estimated that 
the probability of vertical ZIKV transmission is about 20 to 30%, but 
symptoms do not always develop immediately in newborns after infection 
[104]. It is believed that other neurocognitive problems, not well understood 
and recognized, are also due to the ZIKV and can take place after intrauterine 












during birth have been linked to neurocognitive development and some 
neurological and anatomical anomalies in children that do not exhibit 
microcephaly have been reported after intrauterine exposure to ZIKV [105]. 
Additional research is needed to evaluate and understand the molecular basis 
of virus placental infections. 
 
3. SARS-CoV-2, Zika, and Mycoplasma presentation during 
pregnancy and its pathophysiological and molecular correlations  
 
3.1. Pathogenesis and clinical forms of presentation of SARS-CoV-2 during 
pregnancy 
Based on available information the USA Centers for Disease Control and 
Prevention (CDC) has declared that pregnant women appear to have a similar risk 
of presentation of COVID-19 disease as the non-pregnant adult population (85%, 
10%, and 5%, respectively) [106,107]. In addition, the most common initial 
symptoms of COVID-19 in pregnant women are quite similar to those reported for 
non-pregnant patients, such as fever, cough, shortness of breath, and diarrhea [59]. 
However, it is worth mentioning that pregnant women with comorbidities are at 
increased risk of developing severe COVID-19 illness requiring mechanical 
ventilation [52]. Although various reports indicate that pregnancy does not 
intensify the severity of maternal disease caused by SARS-CoV-2, increased case 
numbers of preeclampsia and preterm birth have been reported in women with 












Pregnant women are substantially more susceptible to viral respiratory 
illnesses that are associated with higher morbidity and mortality rates [108]. 
During pregnancy, the physiological ventilatory changes make pregnant women 
more susceptible to infection by lightweight airborne viral particles. The 
decreased FRC and consequent hyperventilation increase the chance of inhaling 
airborne pathogens like the SARS-CoV-2 virus. In addition, the adhesion of the 
virus particles to cells is benefited by the high levels of progesterone found during 
pregnancy, which hinders viral clearance [109]. Because of these reasons, 
pregnancy is usually considered a condition of high susceptibility to viral 
infections, especially to those directly affecting the respiratory system, such as the 
SARS-CoV-2 virus. This is especially apparent during the third trimester. Certain 
symptoms, such as shortness of breath, can be normally reported in some pregnant 
women without COVID-19 disease, and it should be differentiated from the 
changes mentioned above in section 1 of this review. The higher respiratory 
demands of pregnant women may also promote the need for mechanical 
ventilation during the first hours of severe presentations of COVID-19 disease 
with severe acute respiratory distress syndrome [48,110–113], but this rarely 
results in death [114,115].  
Recent investigations have suggested the presence of co-infections in 
patients with SARS and MERS infections, in particular co-pathogens like 
Streptococcus pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, 
Chlamydia pneumonia, among other possibilities [116]. These co-pathogens, 












determinant of a fatal disease course [117]. For example, Mycoplasma pneumonia 
has been found in COVID-19 disease, and the types and severity of signs and 
symptoms in these patients could be due, in part, to this co-pathogen and/or other 
bacterial and viral co-infections [117]. Thus, the co-infections found in patients 
with COVID-19 disease might be extremely important in determining the 
prognosis of the disease due to the promotion of a pro-inflammatory state and 
other conditions important in influencing survival.  
3.1.1 The importance of ACE 2 receptors in pregnancy and SARS-CoV-2 
pathogenesis 
An important unifying concept during pregnancy is that at the molecular 
level there is an increased expression of the angiotensin-converting enzyme 
receptor type 2 (ACE2), and this is routinely seen in pregnant mammalian 
kidneys. ACE2 plays a central role in the regulation of blood pressure [118,119]. 
As a membrane-bound aminopeptidase enzyme, ACE2's main function is to 
hydrolyze angiotensin I into angiotensin 1-9, as well as to transform angiotensin II 
into angiotensin 1-7 (MasR) [118,119]. This type of enzyme reaction has 
physiological relevance, especially when taking into account the changes in 
vasoactive substances starting from a vasoconstrictor agent like angiotensin II. 
The role of angiotensin II is to raise blood pressure upon binding with the 
Angiotensin type I receptor (AT1R) and also to be converted into vasodilator 
agents such as angiotensin 1-7. This latter conversion will contribute to lowering 
blood pressure through MasR agonism and AT1R antagonism, leading to the 












[118,119]. We will discuss below the ramifications of this finding for women who 
are pregnant with certain viral infections like infections caused by SARS-CoV-2 
virus. 
Regarding SARS-CoV-2 infectivity and its effects before and during 
pregnancy, it is important to consider the distribution of ACE2 receptors in 
women and how pregnancy affects this [120]. The ACE2 receptor is an important 
component of the RAS axis. It is a zinc metalloprotease, expressed in several 
tissues and organs, and it is also the molecular receptor for the SARS-CoV-2 virus 
that binds to this protein through the S protein on its surface, during the initial 
steps of cell infection [119]. The ubiquity and variability of expression of this 
receptor in several tissues of the female reproductive tract is intriguing, in 
particular, with regards to how it could explain SARS-CoV-2 pathogenesis and its 
implications in human fertility, the short- and long-term viability of gametes, and 
its possible adverse effects on pregnancy [119,121]. The ACE2 receptor is 
expressed in the vagina, uterus, fallopian tube, and ovary (specifically in ovarian 
gametes) [119–123]. In the ovary, ACE2 seems to have an important role in 
maintaining the balance between angiotensin II and angiotensin 1-7. This balance 
regulates the secretions of hormones like estradiol and progesterone in favor of 
the oocyte maturation cycle as well as the generation and progression of the 
corpus luteum. The expression of ACE2 seems to increase as the oocyte 
maturation cycle progresses [124]. Thus, it is important to consider female fertility 













The abundance of ACE2 receptors that fluctuates during the menstrual cycle 
might make ovary cells more susceptible to SARS-CoV-2 viral infection and also 
susceptible to the effects of ACE2 blockade.  This could have important 
implications in the ovulation process, and consequently in female fertility [119]. 
In guinea pigs, which seem to be similar to humans with regards to ACE2 and 
angiotensin 1-7 (Ang 1-7) expression, ACE2 expression played a critical role in 
the decidualization process, trophoblastic invasion, and also in regulating 
placental blood flow [81]. Based on previous reports researchers have maintained 
that human fertility might be compromised by SARS-CoV-2 infections, especially 
in males, though the impact of SARS-CoV-2 in human fertility is still 
controversial and further studies are needed  [124–133]. It has been recommended 
that non-pregnant, fertile women that have recently acquired SARS-CoV-2 
infections have a close follow-up consultation until more evidence is available 
[119]. Table 1 summarizes the locations where ACE2 expression could affect 
human fertility and pregnancy in females as well as its possible function. 
Importantly, there is also an incremental change in the expression of ACE2 
receptors during pregnancy [134]. Given its binding to the ACE2 receptors, the 
SARS-CoV-2 virus can cause a down-regulation of the RAS axis. This is a 
possible trigger of cardiovascular pathologies that could plausibly affect not only 
a pregnant women´s health but also the health of her fetus [135]. According to 
experimental evidence, ACE2 knockout mice have low levels of Ang 1-7 that 
have been associated with preeclampsia and intrauterine growing restriction as 












concentrations contributes to low blood flux and a subsequent restriction in fetal 
nutrition [119]. The main organs and tissues where ACE2 expression increases 
during pregnancy are shown in Table 1 (left column). Also shown is the role of 
ACE2 receptors located in those organs and tissues during pregnancy (right 
column). Since the ACE2 receptor is the plasma membrane binding site for the 
SARS-CoV-2 Spike protein and is necessary to allow virus entry into host cells, 
all the organs and tissues with increased expression of ACE2 receptors are 
potential sites of infection of SARS-CoV-2 in pregnant women. 
 In the lungs,  SARS-CoV-2 virus infects host respiratory epithelial cells 
through the ACE2 receptor, expressed primarily in type II alveolar cells, although 
ACE2 is also expressed in many extrapulmonary sites [108]. The mechanism of 
entry of the SARS-CoV-2 virus into a host cell is initiated by binding of the S 
proteins to ACE2 receptors on the cell surface, as it is with the SARS-CoV-1 
virus. However, the affinity between the SARS-CoV-2 S protein and ACE2 is 
much higher than that with the SARS-CoV-1 S protein [109]. Despite the 
relatively low general case fatality rate (CFR) estimated at 2.3% in SARS-CoV-1 
and MERS, SARS-CoV-2 is much more contagious, and this could explain, in 
part, the increased deaths in absolute numbers in COVID-19 disease [136]. 
Concerning the susceptibility of pregnant women to COVID-19 disease, they may 
be more vulnerable to SARS-CoV-2 viral infection because of their increased 













ACE2 receptors are also abundant in the heart, explaining the observation 
that during generalized SARS-CoV-2 infections, hearts might be affected. 
Because of this, the SARS-CoV-2 virus is a potential cause of cardiac 
inflammation and heart failure, and this can be more severe during pregnancy 
because of the higher heart function demand in pregnant women, especially those 
with severe COVID-19 illness [137]. Consistently, some cases of 
cardiomyopathies in pregnant women with COVID-19 disease have been 
reported [138]. In summary, the increased heart rate and stroke volume were seen 
in the second trimester of gestation, during labor, and immediately after delivery, 
which could result in heart failure in pregnant women with COVID-19 disease 
and cardiac comorbidities. This could be especially apparent during more severe 
forms of presentation of the illness when pregnant women have a lower cardiac 
function reserve and their hearts are already stressed by these s physiological 
events (section 1, this review). 
As mentioned above, the vertical transmission of the SARS-CoV-2 virus 
from the mother to the offspring seems to be quite rare [59,106,139,140]. In vitro 
fertilization experiments using infected oocytes do not support evidence for 
vertical transmission nor alterations in fertilization [124]. Concerning embryonic 
implantation, although ACE2 endometrial expression has proved to be low, its 
levels increase during the first half of the secretory phase, which could mean that 
the blockade of this receptor by the virus could have some impact on the viability 












Cases of preeclampsia and preterm birth have been reported and are more 
common in severe COVID-19 presentations [140,141]. It is more common to 
observe a preeclampsia-like syndrome in pregnant women with COVID-19 
disease than the classical preeclampsia presentation during pregnancy [142]. At 
variance with classical preeclampsia, in which some typical biomarkers/signs of 
this syndrome are correlated with an increase in uterine artery pulsatility index 
(UtAPI) and angiogenic factors (soluble fms‐like tyrosine kinase‐1/placental 
growth factor [sFlt‐1/PlGF]), these biomarkers are usually not increased in the 
preeclampsia-like syndrome of pregnant women with COVID-19 [142].  
A nearly two-fold increase in the incidence rate of pre-term deliveries as 
well as stillbirths (fetal death at >24 weeks gestation) has been reported for 
pregnant women with SARS-CoV-2 infections [143,144]. The genes associated 
with very early preterm birth and pathophysiological alterations associated with 
these cases involve growth signaling, inflammation, and immunity-related 
pathways, as discussed above in the overview of physiological changes (section 1, 
this review). SARS-CoV-2 infections promote the alterations that favor preterm 
birth and stillbirth, especially in pregnant women with more severe COVID-19 
disease [145]. The increment in cases of preeclampsia and preterm birth caused by 
SARS-CoV-2 infections have also been linked, at least partially, to the 
hemodynamic changes during pregnancy described previously (section 1, this 
review). In association with this, the expression and activity of the ACE2 receptor 
linked to the RAS response increases concerning their linkage to negative 












the body, and as such many organs can be affected by SARS-CoV-2 infection.  In 
particular, ACE2 receptor expression has been shown to increase in single-cell 
transcriptome studies at the maternal-fetal interface as well as in some fetal organs 
[146]. This could be the pathophysiological basis of the preeclampsia-like 
syndrome observed in some pregnant women with severe COVID-19 disease 
[142].  
 
3.1.2 Special considerations regarding immunological, hematological, and 
kidney changes implicated in SARS-CoV-2 pathogenesis and prognosis 
The immunological changes occurring during pregnancy could play a 
central role in determining the rate of progression towards severe cases in SARS-
CoV-2 infected women. These immunological changes lead us to hypothesize 
that pregnant or recently pregnant women, infected by SARS-CoV-2, are at 
higher risk of developing more severe presentations of COVID-19 disease 
according to surveillance by the CDC and the US Public Health Service in the 
USA [147]. From an immunological perspective, pregnancy is linked to maternal 
immunological adaptation that is dependent on the gestational stage; therefore, 
infection with the SARS-CoV-2 virus during pregnancy may result in a variable 
inflammatory response. The relative anti-inflammatory responses seem to vary 
during pregnancy. The anti-inflammatory responses are less compromised during 
the first and third trimesters of gestation. These trimesters compared to the rest of 
the pregnancy yield more risk for the development of CS, leading to more severe 












[148]. The inflammatory cascade or CS promoted in the host by SARS-CoV-2 
could play a key role in the development of ARDS, leading to the development 
of the most severe cases of COVID-19 disease during the first and third 
trimester, or immediately after delivery [149,150].  
In patients that have severe COVID-19 disease with interstitial pneumonia 
elevated serum levels of proinflammatory cytokines have been found. CS and its 
clinical manifestations are characterized by increased plasma concentrations of 
various proinflammatory cytokines, such as IL-1, 2, 6, 7, and 10; granulocyte-
colony stimulating factor, tumor necrosis factor-alpha (TNF-α), interferon γ-
inducible protein (IFN-γ), and several others [109,151,152]. Thus, elevated 
proinflammatory cytokine levels are a key factor in the development of CS with 
subsequent progression to ARDS. CS is also importantly involved in 
Macrophage Activation Syndrome (MAS) that is associated with severe 
presentations and death, especially in children with chronic rheumatic diseases 
[153]. The hyperactivation of the immune response initially can be restricted to 
the lung parenchyma and lymphoid tissue of alveolar bronchi, and later the 
pulmonary vasculature where it promotes vascular dysfunction promoted by 
MAS-like inflammation. The MAS-like inflammation and vascular dysfunction 
can result in pulmonary intravascular coagulopathy with micro thrombosis and 
hemorrhage. That is why measuring the levels of the proinflammatory cytokines 
like IL-6 produced via macrophage activation induced by a Th1 immune 
response is considered as a biomarker and predictor of poor prognosis in 












thought to be beneficial, because of its anti-inflammatory action, decreasing the 
risk of vascular thrombosis.  
Hematological alterations related to coagulation during COVID-19 disease 
have been reported [155–157]. It should be appreciated that the most severely ill 
patients present with coagulopathy and disseminated intravascular coagulation 
(DIC), and the most typical features found are the higher levels of D-Dimer and 
Fibrinogen Degradation Products (FDP) and prothrombin prolongation. Although 
the mechanisms of coagulopathy are not fully known, it is estimated to play a key 
role in the involvement of dysregulated immune responses directed by 
inflammatory cytokines, lymphocyte cell death, hypoxia, and endothelial damage 
[158], as mentioned in the paragraph above and in section 1. As the levels of 
fibrinogen, D-Dimers, and coagulation factors found in plasma increase with a 
decrement of APTT and prothrombin times, pregnancy by itself is associated 
with increased thromboembolic risk, and during infection, with the SARS-CoV-2 
virus, the risk might be greatly increased due to additional coagulation changes 
[155]. 
Because of the diminished functional reserve of the kidneys during 
pregnancy (section 1, this review), there is an additional increase in kidney 
diseases. Some women have been found to have chronic kidney disease 
for the first time during pregnancy [159]. Around 20% of women who develop 
early pre-eclampsia (≤30 weeks gestation), especially those with heavy 
proteinuria, have previously unrecognized chronic kidney disease [160]. Taking 












affects pregnant women in more severe ways, especially in those women that 
have kidney comorbidities. Pregnant women with COVID-19 and kidney 
diseases are a high-risk group that should be managed by a multidisciplinary 
team approach, including a nephrologist and neonatologist [161]. There are some 
reports of acute tubular necrosis in pregnant women with COVID-19 disease, 
possibly due to the extreme functional demand of kidney function during 
pregnancy and medications received to treat COVID-19 symptoms [143,162]. 
Because of this, the impact of medications on the kidneys during treatment of 
COVID-19 and other diseases in pregnant women has to be taken into special 
consideration. 
 
3.2 – Pathogenesis and clinical forms of presentation of Zika Virus during 
pregnancy 
Zika virus (ZIKV) disease is usually acute and self-limited. Transmission 
of ZIKV can occur via a vector or non-vector-borne process. The cycle of the 
vector-borne transmission of ZIKV (the most frequently observed), starts via 
virus acquisition by mosquitoes (mostly Aedes Agypti and Ades Albopictus) 
during a blood meal, similar to the insect-borne vectors that cause Dengue and 
Chikungunya diseases. When the virus replicates inside mosquitoes and 
eventually reaches the salivary glands, it can be secreted and subsequently 
injected into a new host during the next blood meal.  In its new human host, 
ZIKV can replicate in fibroblasts, keratinocytes, and immature dendritic cells in 
the skin [163]. Then the replicated virus can penetrate lymphatic vessels and 












humans can last from 3 to 12 days [164]. This period is followed by an illness 
state with several forms of presentation. In most patients, ZIKV is asymptomatic 
(80% of cases), and it can be present also as a moderate dengue-like fever disease 
(20% of cases). During this period, the virus can be found in patients´ blood 
[165]. The symptoms found during a moderate disease course are fever, macular 
or papular rash, conjunctivitis (red eyes), arthralgia, headache, myalgia, and 
occasionally retro-orbital pain [165]. These symptoms are usually present 
between 4 and 7 days after infection [166,167]. 
It can be difficult to distinguish ZIKV symptoms from those produced by 
diseases caused by other Arboviruses, especially Dengue and Chikungunya. An 
exanthema (pruriginous maculopapular rash) that starts in the face and/or trunk 
suggests ZIKV infection [104,168]. ZIKV can also have complications and 
sequelae like the Guillain-Barré syndrome and hemorrhagic symptoms [169]. 
Guillain-Barré syndrome is an autoimmune disease of the nerves, starting with 
weakness to later present as flaccid paralysis. A temporal coincidence of 
Guillain-Barré syndrome with ZIKV has been found.  Guillain-Barré syndrome 
patients found in ZIKV outbreaks were found to have high levels of IgM 
antibodies against ZIKV. They also experience rapid development of 
neurological symptoms [170].   
The hemorrhagic complications during ZIKV infections are usually mild 
[171]. ZIKV infections are in general systemic, and the virus can be found in 
body secretions for weeks after the infection [172]. ZIKV also shows positive 












for months after infection, and thus ZIKV infection is considered a sexually 
transmitted disease (STV) [173]. The non-vector-borne transmission of ZIKV 
occurs by sexual, transplacental, or perinatal transfer as well as accidents in the 
laboratory or during blood transfusions. This ability of ZIKV to be acquired by 
human-to-human transmission makes ZIKV unique among other Flaviviruses. 
 
The possibility of acquiring a ZIKV infection during pregnancy and 
displaying clinical symptoms are not modified by the pregnancy itself [104]. 
Most of the ZIKV-infected women who are pregnant are asymptomatic or 
paucisymptomatic. Nor has ZIKV been described as causing a more severe 
infection or a major risk for complications in the mother during pregnancy. The 
non-vector-borne transmission of ZIKV is sexual, transplacental, perinatal, or 
due to laboratory accidents or blood transfusions. The vertical transmission of 
ZIKV can happen at any time during pregnancy. When the infection by ZIKV 
takes place in the mother, it is irrelevant if the mother was displaying symptoms 
or was without symptoms for the vertical transmission to occur.  
The outbreaks reported in French Polynesia between 2013 and 2014 and 
Brazil in 2015 were important in establishing the association between ZIKV 
infection, Guillain-Barré Syndrome, and microcephaly. Other less frequent 
complications can occur, usually in less than 1% of ZIKV patients, and can 
include transverse myelitis, meningoencephalitis, myocarditis, and 
thrombocytopenic purpura [104,174,175]. In 2015, Brazil reported an increase in 












country, which was temporally associated with an outbreak of ZIKV infections. 
The WHO declared a public health emergency due to the observed effects of 
ZIKV in Brazil and the spread of the ZIKV from Brazil to Argentina in 2016 
[176–178]. 
ZIKV complications, such as teratogenesis linked to the ZIKV, are 
related to an ample spectrum of fetal malformations whose landmark is the 
congenital Zika syndrome. Other malformations have been described, such as 
those in the genitourinary tract, skeletal muscle, ophthalmologic, and lung and 
craniofacial malformations, among others [89,179]. In particular, almost 30% 
of ZIKV-infected children have significant vision anomalies due to the 
infection of retinal cells and optical nerves [180]. In addition, congenital 
alterations due to ZIKV have also been described as an incremental increase in 
the risk of spontaneous abortion, fetal death, low weight at birth, preterm birth, 
and restriction to intrauterine growth [89,102,178]. Supporting evidence is the 
finding of ZIKV antigens and nucleic acids in the amniotic fluid, the placenta, 
and the fetal tissues in most of the cases described in places where outbreaks of 
ZIKV have been confirmed [93]. 
The diagnosis of ZIKV infections in pregnant women and their 
offspring can be difficult because the detection of the ZIKV genetic material 
occurs during a limited time in the infected mother, and also because a fetal 
infection can be present for several months or years later [104]. Though a PCR 
assay for the ZIKV in the amniotic fluid can be useful on some occasions, it is 












magnetic resonance, play a chief supporting role in the diagnosis of fetal viral 
infections during pregnancy. These diagnostic tests should be carried out in 
endemic regions or in people returning from endemic regions, especially in 
patients with Guillain-Barré-like syndromes and pregnant women suspected of 
having ZIKV infections [169]. In these regions, organs and blood donations 
should be also tested for ZIKV infections [181].  
There is no specific treatment for ZIKV during the infection process, and 
there are no specific and effective antiviral drugs available to treat ZIKV in 
neonates. The recommendations are to treat ZIKV symptoms and provide 
support treatments [176]. Prevention and control, including avoiding mosquito 
bites, are the main protective measures available to avoid ZIKV infection, such 
as the use of mosquito repellent, adequate clothes, mosquito nets, among other 
approaches. Vector control, blood and tissue bank tests, and prevention of 
sexual and vertical transmission are also useful as reinforcement and protective 
policies.  
As of the preparation of this contribution, there were no available 
vaccines against the Zika virus to prevent the disease, though some vaccines are 
currently under development and are being tested [176]. Some advances in 
antiviral therapeutics and vaccines are under investigation but remain at an early 
phase of development. The preconception recommendations and also those 
during pregnancy to avoid being infected by ZIKV are the only methods 
available worldwide to currently prevent vertical transmission. In many 












anti-conception methods, and safe abortion procedures are out of reach for many 
women, particularly in Africa and in some Latin-American countries. Though 
during 2020, the scientific community and the world have paid attention to the 
SARS-CoV-2 pandemic, ZIKV is also an important public health problem in 
many countries around the world [182].
 
 
3.3 – Pathogenesis and clinical forms of presentation of Mycoplasma during 
pregnancy 
 
The adherence of mycoplasmas to host cells is a prerequisite for its 
pathogeneses, and the cell adhesion membrane protein-lipoproteins (adhesins) 
from mycoplasmas play an essential role to achieve this. For example, an 
adhesion molecule has been found in Mycoplasma genitalium (M. genitalium), a 
140 kD protein, and it is probably the most studied adhesin molecule isolated 
from mycoplasmas [183,184]. The M. genitalium adhesion molecule is expressed 
on a distinctive, protruding curved terminal organelle that appears to be important 
for cell adhesion and motility of this mycoplasma. The proteins and array of this 
organelle have strong similarities to those found in Mycoplasma pneumoniae 
[185]. The proteins and array of molecules in this organelle have strong 
similarities to similar molecules found in Mycoplasma pneumoniae [185]. To 
achieve cell adhesion rapid antigenic variations of the surface proteins of 
mycoplasmas occur, which also allows them to evade the immune responses of 
the host [185]. The successful colonization of host cells, in addition, appears to be 
determined by the synthesis of mycoplasma bacterial endotoxins and other non-












locally produce host cytokines and chemokines [186]. The secretion of endotoxins 
and cytokines can also stimulate the synthesis and release of prostaglandins, 
which in turn can activate proteases and other bioactive substances that can lead 
to adverse pregnancy outcomes [187]. As mentioned above, several Mycoplasma 
species, their membranes or their membrane components can directly activate 
macrophages and monocytes, leading to the expression and secretion of important 
pro-inflammatory cytokines like TNF- α and several interleukins (IL ‐ 1, IL ‐ 1β, 
IL-6, IL-8, IL-12, IL-16) and interferon-γ [184]. Mycoplasma infection and 
resulting inflammation, either local or systemic, are important in producing 
deleterious symptoms during pregnancy. After the adhesion and entry of 
mycoplasmas into host cells, several mycoplasma metabolites can cause cellular 
damage and can interfere with the normal cellular metabolism [183,184]. 
Mycoplasmal infections during pregnancy have been linked with certain 
complications and neonatal risks, and this aspect of mycoplasma and disease has 
been debated for many years [188]. Since these pathogens are generally able to 
colonize mucosal tissues, the maternal vaginal colonization by some 
Mycoplasma species, such as M. hominis and M. genitalium, can be an important 
risk factor in the occurrence of ascending intrauterine infection and/or during 
fetal passage through the birth canal. Concerning M. hominis, its vaginal 
presence during bacterial vaginitis (BV) is associated with pre-term delivery and 
spontaneous miscarriage, as is also found with M. genitalium infections [188]. In 
addition, it should be noted that during pregnancy the vaginal microbiome 












and estrogens, resulting in an increase in the abundance of Lactobacillus spp., 
commonly known to be a lactic-acid producing bacteria, leading to a decrease in 
vaginal pH, which is protective against most bacterial and viral pathogen 
infections [189].  
As mentioned above in various cases, certain mycoplasmas can colonize 
the urogenital tract, whereas other mycoplasmas, such as M. pneumoniae, 
primarily colonize the respiratory tract. However, various mycoplasmas can 
disseminate through the bloodstream during or after a respiratory tract infection 
and spread to the placenta. Interestingly, vertical transmission cases of invasive 
M. pneumoniae are relatively rare [45]. However, certain associations between 
M. pneumoniae during pregnancy and hematological complications, such as 
hemolytic anemia, are among the most common pregnancy complications. Less 
frequently found are:  thrombocytopenia, thrombotic thrombocytopenic purpura 
(TTP), DIC, aplastic anemia, hemophagocytosis, and transient acquired thrombin 
deficiency [190].  
Premature labor (PL) is often classified following clinical presentation as 
spontaneous premature labor (SPL) (50% of cases), premature rupture of 
membranes before labor (PRMBL) (30% of cases), and medically induced 
premature labor (MIPL) (20% of cases) [191]. Although there are multifunctional 
causes to these complications of pregnancy, several pathogenic microorganisms 
have been associated with PL, especially during their movement from the lower 
genital tract, entering and invading the chorioamnion, followed by 












The detection of bacteria, including various Mycoplasma species, in the amniotic 
fluid (AF), is a significant finding, because the AF is usually sterile in women 
that are not in labor. Extraction of AF with positive cultures for bacteria and/or 
mycoplasma (it should be noted here that mycoplasmas rarely grow in such 
cultures) is found in 13% of the women under SPL with intact membranes. In 
those women that enter into labor prematurely positive cultures for bacteria in the 
AF increase to 22%. Cultures can be positive for pathogenic bacteria in up to 
32% of the women with PRMBL before labor, though it increases to 75% at the 
moment of labor [192]. When these situations arise during pregnancy, the 
frequency of positive AF cultures increases.  
With regards to BV, several studies have shown that asymptomatic or 
symptomatic BV elevates the risk of having a spontaneous abortion or preterm 
labor [193]. Usually, late-term abortions and preterm deliveries during pregnancy 
are considered together when analyzing their causes, as they share many 
etiological factors. After the 2000s, congenital fetal infections were documented 
at higher frequencies compared with the frequencies found before the 2000s. 
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pregnancy are born with bacteriemia, usually with M. genitalium and 
Ureaplasma species. M. hominis has been isolated in 24% of the patients during 
preterm labor and in 8% of those without preterm labor. This difference was not 
considered statistically significant. However, higher numbers of M. hominis 
(≥105 units, measured as color change units) have been detected in patients with 












high numbers of these microorganisms are found, it appears to be a signature of 
BV. Though M. hominis is likely to play a role in BV per se, and as a 
consequence of the adverse results of pregnancy, it is not known if this is a 
peculiarity of BV or if this can also be applied to other bacteria that can play an 
important role in BV. As expected, it is relatively common to find low numbers 
of M. hominis in the absence of BV, where it is likely that adverse pregnancy 
outcomes will not occur [194].  
Bacterial transmission from the mother to offspring can happen after 
intrauterine infection where the bacteria can multiply in the AF and also be 
transmitted to the fetal lungs. This type of infection can also happen at the 
beginning of pregnancy where epithelial membranes are intact. Alternatively, 
hematogenous infections can occur that involve the umbilical blood vessels in an 
infected placenta. Finally, infections may also happen through the respiratory 
mucosa or the skin, while the newborn is being delivered during labor.  
The pathogenic effects of mycoplasmas during pregnancy and their 
adverse effects in various tissues are currently under study, including special 
attention being directed at premature contractions that can induce premature labor, 
preterm labor, spontaneous abortion, and other adverse events. Their role in 
neonate infections is also under study. For example, M. genitalium, Ureaplasma 
parvum, and Ureaplasma urealyticum can be sexually transmitted, and thus they 
are sexually transmitted diseases. Other afflictions occur due to mycoplasmal 
infections, such as infertility, and illnesses such as urethritis in men, and pelvic 












associated with bacteria in the AF and placenta, these bacteria are not routinely 
sought in pregnant women, probably because it is quite difficult to grow 
mycoplasmas in cultures outside the body and the need to perform only routine 
diagnostic PCRs. The association between various pathogens and complications 
of pregnancy has been investigated more intensely during recent years [195]. 
Next-generation sequencing (NGS) can detect the microbial cell-free DNA in the 
maternal plasma of women with clinically and/or histologically evident 
chorioamnionitis, but this usually does not include intracellular species of 
bacteria. Differences among the microorganisms living in the genital microbiota 
have been observed when comparing pregnant women under preterm labor or 
delivery to term and healthy labor. The most frequently observed bacterial species 
are Lactobacillus spp., and these species are abundant in the specimens obtained 
during delivery at term and healthy labor. U. parvum, M. hominis, and 
Haemophilus influenza were found almost exclusively when there was 
chorioamnionitis. Streptococcus mitis, U, parvum, and M. hominis were 
significantly correlated between paired samples of maternal plasma and umbilical 
cord, suggesting that several associated defects in pregnant women and fetuses 
like those reported above are caused by these colonizing pathogenic 
microorganisms [196,197].  
Until recently, most diagnostic studies on fetal infections were performed 
with cultures of AF or performing molecular tests directly on the AF [198]. 
However, there could be complications with this approach. For example, Oh et al. 












preterm delivery do not show any evidence of amniotic inflammation when 
cultures or molecular assays were performed using AF. Nearly 66% of the patients 
showed negative AF cultures when there were signs of infection by other 
methods. This demonstrates that the in vitro cultures of AF represents a low 
sensitivity method for the diagnosis of AF infections. Also, amniocentesis is an 
invasive procedure with additional medical risks. 
 The results obtained with NGS have identified many common 
microorganisms as part of the infections found during pregnancy complications, 
including those microorganisms that we know are specifically pathogenic and 
thought to be causing chorioamnionitis [196]. The examination of NGS cell-free 
microbiological DNA in plasma is a fast non-invasive test that can be achieved 
after obtaining small amounts of maternal plasma. However, this procedure is 
unlikely to be useful in the diagnosis of mycoplasmal infections, because these 
microorganisms are rarely found in plasma. This method aims to diagnose 
infections during pregnancy using the maternal plasma without the need of 
performing risky amniocentesis procedures. This allows an appropriate 
therapeutic approach using the correct antimicrobials before and after delivery. 
This should be an improvement over the current methods used to diagnose 
intrauterine microbial infections during pregnancy, because antimicrobials like 
antibiotics can alter the neonate microbiota and have toxic effects, and this would 
be avoided. This diagnostic technique seems to be promising to identify possible 














4 – Special considerations about the neonates and breastfeeding 
 
4.1 - COVID-19 disease 
 
As of this date, the vertical intrauterine transmission of viral and bacterial 
pathogens remains under investigation, especially in COVID-19 disease, and 
recent determinations of the rates of SARS-Cov-2 infection seem to be 
independent of the mode of delivery in newborns. The most probable way of 
acquiring the virus for a newborn is through respiratory droplets from the mother 
or other infected household contacts, or eventually by direct contact with 
contaminated surfaces [49]. There has been no demonstration of breastfeeding 
transmission in neonates from mothers with COVID-19 [200]. The symptoms and 
the most common methods of transmission in neonates for the diseases such as 
COVID-19 are summarized in Fig. 3.                                                                                                                                                          
The pandemic behavior of the SARS-Cov-2 virus excludes partially the 
newborn period since the incidence of transmission of this infection in this group 
is uncommon. The clinical presentation of COVID-19 disease is frequently 
asymptomatic or a mild disease process with low to moderate morbidity, without 
requiring hospitalization. Some factors thought to be important in diminishing the 
severity of SARS-CoV-2 infections in neonates and children compared to adults 
are: (i) the differences in the intensities of innate and adaptive immune responses 
to infections and injuries; (ii) exposure to more diverse infectious pathogens that 
are increasing in frequency and concurrency; (iii) pre-existing immunity to some 












melatonin than in adults; (vi) protective side-effects of required vaccines and (vii) 
reduced exposure to SARS-CoV-2 virus compared to adults [201]. Severe illness 
presentations of COVID-19 disease have been reported, even if generally 
considered uncommon. It is certainly possible that SARS-CoV-2 infections can 
occur in preterm or neonates with underlying medical conditions. This makes 
these newborns potentially at risk of developing severe COVID-19 symptoms 
[55]. There have also been reports describing newborns with symptoms similar to 
COVID-19 that required admission to a neonatal intensive care unit (NICU) 
because of fever, augmented labored breathing, gastrointestinal symptoms, 
tachycardia, and signs of pulmonary infection. Interestingly, several babies with 
symptoms of COVID-19 disease tested negative for the SARS-CoV-2 virus. Only 
40% of these patients had positive tests for SARS-CoV-2 [48,49,55,202–204].  
It is difficult to determine at this time whether full-term neonates during 
the first month of life diagnosed with COVID-19 follow a similar clinical course, 
compared to older children. This could be due, in part, because the immune 
system in the early stages of life has unique characteristics [205]. The possible 
way that neonates fend off viral (and bacterial) infections in the absence of 
maternally transmitted IgG antibodies could be directly related to their innate 
immune systems and the presence of larger numbers of immature T cells. This is a 
general characteristic of newborns that makes them generally less vulnerable to 
nearly all viral infections, including those caused by coronaviruses. The SARS-
CoV-2 virus has the potential to be systemic in neonates, affecting multiple 












frequent presentations of COVID-19 found in neonates are fever and a respiratory 
tract infection, and they also display other mild symptoms, such as nasal 
congestion, tachypnea, reduced feeding, or more severe signs, such as cyanosis, 
fatigue, and oxygen requirement, and even ARDS. Gastrointestinal tract 
symptoms are occasionally present, and in exceptional cases, central nervous 
system symptoms (e.g. seizures) have been found. The most common course of 
COVID-19 disease in children is the complete recovery from the illness, but in 
exceptional cases, a fatal outcome has occurred [207]. With regards to Regarding 
a mother’s infection with SARS-CoV-2 during pregnancy and the subsequent 
transmission of maternal IgG antibodies to the fetus via placental route or to the 
newborn via breastfeeding, there is no evidence of protection mediated by 
mother’s breast milk [208]. 
Although respiratory transmission is the primary route for SARS-CoV-2 
infectivity, the oropharyngeal presence of SARS-CoV-2 RNA in both urine and 
stool in the baby is an important finding because these sources could serve as 
additional vehicles for virus transmission. Whether the virus detected in urine and 
stool is viable and infective requires further investigation. As preventive 
measures, caregivers should be counseled to wear face masks and practice proper 
hand-washing, especially when changing the diapers of neonates, to prevent the 
spread of the SARS-CoV-2 virus among household contacts [209].    
 













In recent years evidence has accumulated of an association between ZIKV 
infection during pregnancy and a syndrome characterized by fetal microcephaly.  
Microcephaly is a severe brain developmental disorder, which is accompanied by 
impaired cognitive functions and neurodevelopment. In the case of ZIKV, this can 
involve the arrest of brain growth and partial collapse of the skull [210,211]. 
Neonates that were exposed to ZIKV through vertical intra-uterine 
transmission had several symptoms and affections linked to ZIKV infections of the 
mother during pregnancy [212,213]. A pattern in newborns that had intrauterine 
exposure to ZIKV has been described as five characteristics that have been termed 
congenital Zika syndrome. These are: (a) severe microcephaly with partial skull 
collapse, (b) narrowing of the cerebral cortex with subcortical calcifications, (c) 
ophthalmologic sequels with macular scars and focal pigmentation in the retina, (d) 
congenital contractures of one or several joints, and (e) early hypertonia with 
extrapyramidal failure [103,212,213]. It is unclear if mild neurocognitive issues 
and other disorders are linked to ZIKV infections [211,214]. Most of the cases of 
transmission by ZIKV occur via a vector, such as the Aedes mosquito. However, as 
pointed out above, transmissions via blood, sexual or vertical routes have been 
confirmed with ZIKV [215,216].  
Manifestations due to mother-to-child transmissions of ZIKV have been 
detected before birth, at the time of delivery, or later. This suggests that when 
ZIKV disease appears months or even several years after birth, these diseases or 
manifestations could be due to events that occurred during pregnancy or at birth. 












infections, such as microcephaly, are calcifications at the cortical-subcortical level, 
the union of the white matter, atrophy in the parenchyma, agenesis/hypoplasia of 
the corpus callosum, cerebellar and brainstem hypoplasia, and lissencephaly-
pachygyria [217].  Currently, the transmission of the ZIKV has not been detected 
via breast milk, although the virus has been detected in breast milk samples [218]. 
Therefore, current evidence suggests that breastfeeding of infected mothers should 
be maintained as usual with neonates [218].  
Some authors have proposed that the Zika virus be included with the 
traditional TORCH pathogens, because of the similarities in pathogenesis, fetal 
infection, and developmental defects that are caused by the infection. The 
similarities between the congenital disorders that are induced by the TORCH and 
ZIKV pathogens include neurotropism, with specific congenital malformations, 
depending on the gestational age at the time of fetal infection [219]. Additional 
knowledge about the disease(s) caused by ZIKV infections remains to be revealed; 
however, other maternal viral infections that result in the transmission to the fetus 
provide instructive lessons that can be applied to the prospective evaluation of 
ZIKV infections and the diseases that this virus causes. 
One of the most obvious properties of ZIKV is that it can have cytopathic 
effects on various tissues and cell types. Viral antigens have been found in the 
cytoplasm of neurons, especially those with characteristics of degeneration and 
necrosis, and within glial cells. Although there is an absence of substantial 
inflammatory responses in the brain during ZIKV infections, a specific cytopathic 












syndrome [219]. Congenital rubella infections can only be prevented by 
vaccination. The same is expected with ZIKV in endemic areas if an effective 
vaccine can be developed. Diseases caused by congenital cytomegalovirus (CMV) 
infections are probably the diseases that most closely resemble the diseases caused 
by ZIKV infections, since both can produce profound effects on the fetus, such as 
microcephaly, sensorineural hearing loss, chorioretinitis, and other neurological 
defects. The information on CMV infections during pregnancy has provided a 
robust framework for current and future studies of ZIKV infections and the 
diseases that this virus causes. There are similarities in the proposed mechanisms 
of CNS damage in early-occurring CMV and ZIKV infections that occur during 
the development of the CNS. Some of the proposed pathogenic mechanisms are 
virus-induced destruction of neural progenitor cells, alterations in the proliferative 
capacity of neural progenitor cells,  damage to the vasculature, and significant 
structural damage to the central nervous system and spinal cord [220]. 
In addition to CMV, human immunodeficiency virus (HIV-1) infections in 
infants are similar to congenital ZIKV infections in their timing and mechanisms 
of mother-to-child transmission. Like HIV-1, ZIKV-infected infants may be 
asymptomatic at birth but then develop symptoms of the disease within the first 
few months of life.  Few effective treatments currently exist to prevent vertical 
transmission in viral diseases like ZIKV, CMV, and HIV-1. In HIV-1 infections, 
treatment with antiretrovirals has produced reductions in vertical transmission from 












infections will allow the development of new therapeutic strategies that reduce 
fetal ZIKV infections [221]. 
Similar to ZIKV primary maternal infections, primary maternal infections 
by Herpes simplex virus (HSV) are usually asymptomatic [222,223]. However, 
there are also some contrasts between HSV and ZIKV infections, and the data on 
these infections can be analyzed to learn more about them. An antiviral drug exists 
for the treatment of neonatal HSV infections (acyclovir), whereas none is currently 
available for the prevention or treatment of ZIKV infections during pregnancy or 
childhood. Interestingly, when suppressive acyclovir therapy was administered for 
6 months following a newborn HSV infection, an improved neurologic outcome 
was forthcoming, implying that HSV can be suppressed in the CNS without 
causing CNS symptoms. This outcome remains unknown for ZIKV infections 
involving the CNS. 
There remain some uncertainties about the postnatal development and 
evolution of the disease in ZIKV affected infants. Prospective cohort studies for 
symptomatic and for asymptomatic ZIKV-infected newborns whose mothers have 
Zika infections should strengthen our knowledge on the subject. Recent evidence 
indicates that infants with a normal head circumference at birth may still have 
underlying brain and/or eye defects in the first 18 months to 4 years after infection 
with ZIKV [224]. 
 













Mycoplasmas, at least initially during their human colonization, are 
primarily mucosal inhabitants, along with genital mycoplasmas and ureaplasmas 
that colonize the urogenital tract. These mycoplasmas are among the most 
frequently found superficial infections in humans, and at these sites, they rarely 
cause threatening symptoms. However, when mycoplasmas invade further into 
various organs, they can produce more severe signs and symptoms. For example, 
M. hominis, U. urealyticum, and U. parvum are examples of pathogens that can 
invade pregnant mothers and are closely associated with neonatal pneumonias 
[225]. Among the more than 200 known species of Mycoplasma, at least 13 species 
are known to be human pathogens, such as M. pneumoniae, M. hominis, and U. 
urealyticum, which are among the most well-known Mycoplasma species involved 
in various human diseases and conditions, some of which are discussed in another 
review in this special issue [1]. In this section, M. hominis is a relatively 
uncommon infection, but it can cause life-threatening disease in both full-term and 
preterm newborns. In contrast, M. pneumoniae is a commonly found infection, 
especially in atypical childhood pneumonia and other diseases. 
As also discussed elsewhere in this contribution, during pregnancy bacterial 
transmission from a mother to her child can occur via intrauterine infection from 
the blood, via ascending pathways through the genitourinary tract, where the 
bacterium multiplies in the AF and is then transmitted to the fetal lungs, or by the 
passage of the newborn through an infected maternal birth canal. The ascending 
pathway type of infection can occur early in pregnancy when the fetal membranes 












umbilical blood vessels of an infected placenta, causing subsequently an 
intrauterine infection. In this context, infections caused by Ureaplasma spp. can 
result in chorioamnionitis, the spread of infection throughout fetal organs, and the 
inception of congenital pneumonia [227].  Finally, during fetal passage through an 
infected maternal birth canal subsequent colonization of the newborn’s skin, 
mucous membranes, and respiratory tract can occur [228]. 
When intrauterine mycoplasmal infections arise, they are often associated 
with birth complications, such as premature rupture of birth membranes, premature 
delivery, and spontaneous abortion. For example, the identification of Ureaplasma 
spp. inside the chorioamnios has been consistently associated with histologic 
chorioamnionitis and inversely related to birth weight. Such microorganisms can 
invade the amniotic cavity and persist for several weeks when the fetal membranes 
are intact, and subsequently, they can initiate a severe inflammatory reaction in the 
absence of labor. Maternal and fetal colonization by Ureaplasma spp. has also 
been associated with the development of bronchopulmonary dysplasia in preterm 
infants of less than 32 weeks of GA [229]. 
Several Mycoplasma species are considered normal commensals, but at 
least six in the genus Mycoplasma are considered human pathogens, among them 
M. pneumoniae, M. genitalium, and M. hominis [225]. Recently, findings of great 
interest were published indicating that M. hominis infections can produce 
bacteremia, pneumonia, meningitis, among other symptoms in newborns, but the 
significance of M. hominis as a pathogen causing neonatal meningitis remains 












fluid in the absence of other microorganisms, and data that support an independent 
role for this mycoplasma in histologic or clinical amnionitis is modest at best 
[231,232]. Recently reported M. hominis infections in newborns to indicate that the 
clinical findings, which can include pleocytosis with or without inflammatory 
reactions, are not always in agreement with the results obtained by testing of the 
CSF. In addition, M. hominis can be isolated from the CSF of newborns without 
signs of meningitis [230].  
Traditional procedures for the diagnosis of bacteria in the blood and tissues 
have relied on Gram staining, but the lack of bacterial cell wall components makes 
mycoplasmas undetectable by Gram staining. Another diagnostic limitation is that 
the growth of mycoplasmas in bacterial cultures is very slow, limited to only 
certain species, and requires specific growth media, a situation that can lead to 
patients with undiagnosed mycoplasmal infections, such as in cases of meningitis 
and especially chronic illnesses. Unexplained increases in morbidity and mortality 
are often found in patients with undiagnosed mycoplasmal infections [233,234].  
The problems associated with the specific identification of mycoplasmal 
involvement in pregnancy and neonatal infections can also result in poor treatment 
decisions. For example, M. hominis is intrinsically resistant to many antibiotics, such 
as -lactams, glycopeptides, sulfonamides, and macrolides. For this reason, the most 
frequently used antibiotics (-lactams combined with aminoglycosides) in neonates 
suspected of sepsis, are not effective against M. hominis. Since the majority of 
antibiotics active against M. hominis are the tetracyclines, lincosamides, 












clinical course of the newborn patient worsens. This can lead to delays in employing 
more optimal treatments, resulting in more fatal outcomes [230,235]. As discussed 
here and elsewhere [236,237], there are several difficulties related to the clinical 
testing and identification of mycoplasma pathogens in patients with acute or chronic 
diseases, as well as the association of these infections with specific diagnoses. 
Unless these problems can be overcome, the recognition of clinical presentations and 
specific diseases and their infectious causes may result in ineffective empirical 
therapies.  
 
5. Final Comment 
        
Continuing societal exposures to emerging and reemerging infectious diseases are 
among the most challenging threats to our species. Among the pathogens involved, 
we have chosen to focus on three infections that are important in pregnancy and 
neonatal health: SARS-CoV-2 virus, Zika virus, and Mycoplasma species.   
During and immediately after pregnancy there are a significant number of 
physiological changes in the mother and offspring. A temporary organ controlling the 
relationship between the mother´s intracorporal environment and offspring, the 
placenta, must be created. After delivery, neonates have not fully developed all of the 
abilities of their homeostatic systems, and under normal conditions are dependent on 
breastfeeding from their mothers. Pregnant women have an increased risk of developing 
cardiorespiratory, hematological, immunological, and kidney-related diseases, because 
of the physiological adaptations that they must endure for the delivery and development 












risk of developing diseases promoted by certain intracellular pathogens, such as the 
examples discussed in this contribution. Often these microorganisms are difficult to 
diagnose and treat, and any delay in either their diagnosis and/or treatment can lead to 
difficult and potentially life-threatening situations for the mother, the fetus, or the 
neonate.  
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Figure 1. Overview of the physiological changes during pregnancy in the 
mother, the placenta and the fetus and implications in SARS-CoV-2, 
ZIKV and Mycoplasma infections. (A) Scheme showing the 
physiological changes seen during pregnancy in the mother, the placenta 
and the fetus and the main mechanisms of transmission, prevention and 
treatment of the diseases promoted by the infectious pathogens discussed in 
this contribution. The left panel shows the general issues, whereas the right 
panel, presents some of the different diseases discussed in this review.  












Figure 2. The intrauterine environment during human pregnancy. 
(A) Schematic representation of the structure of the human placenta and 
chorioamniotic membranes. Location of placental structures as chorionic 
villi and decidua components are schematized.  The potential routes of 
infection are represented. Ascendant microbial colonization is shown 
(yellow arrow) while the hematogenous via is indicated with a red arrow. 
(B) Schematic drawing of the region indicated in the square showing the 
placental villi. The two types of villi are represented in the scheme: two 
placental floating villi that freely end in the intervillous space and an 
anchoring villi that attaches to the endometrial wall.  The main cell types 
involved in fetal-mother interaction are indicated. (C) Histological 
structure of mature normal placenta showing the placental villi and the 
modifications of the endometrium with the presence of decidual 
cells.  Scale bar: 200 µm 
Size Fig 2: 2 column fitting image (also indicated in the file name) 
Figure 3. SARS-CoV-2 virus, Zika virus and Mycoplasma species in the 
neonate. A scheme summarizing the main symptoms and transmission 
pathways for various diseases in the neonate caused by SARS-CoV-2 
virus, Zika virus and Mycoplasma species.  























































TABLE I – ACE2 expression during pregnancy and its normal function. 
 
ACE2 expression Function 
Ovary 
 
Hormonal secretion influence and further regulation of 
oocyte maturation and luteus corpum. 
Endometrium 
 



























 SARS-CoV-2 virus, Zika virus, and Mycoplasma species infections are 
relevant during pregnancy and neonate outcomes. 
 During and immediately after pregnancy, there are a significant number of 
physiological changes in the mother and offspring. 
 These physiological changes joined to particular characteristics of the 
pathogens mentioned above, are important to understand the pathophysiology of 
these diseases, clinical manifestations, and therapeutics. 
 The molecular interaction of these pathogens and host cells of the mother-
offspring under this physiological context, which yields particular presentations of 
these diseases are discussed.  
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